Clinical Trial Update: Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide? [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating whether ticagrelor’s platelet inhibition efficacy is mediated by endogenous endothelial nitric oxide in acute coronary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Hull University Teaching Hospitals NHS Trust | Conditions: Acute Coronary Syndome | Phase 4 | Status: COMPLETED